A clinical trial to evaluate a drug candidate called cyclodextrin as a possible treatment for Niemann-Pick disease type C1 (NPC), a rare and fatal genetic disease, will start today, researchers announced. Scientists from the NIH’s National Center for Advancing Translational Sciences (NCATS) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will conduct the clinical trial at the NIH Clinical Center. Reaching this trial stage required collaboration among government, industry, patient advocacy groups and academic researchers.

Related posts:

  1. Medicare Card, NIH launches trial for rare degenerative muscle disease treatment Medicare Card, NIH launches trial for rare degenerative muscle disease treatment...
  2. Clinical trial stopped on combination cholesterol treatment The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned. The trial found that adding high dose, extended-release niacin to statin treatment in people with heart and vascular disease, did not reduce the risk of cardiovascular […]...
  3. Medicare Card, NIH launches largest clinical trial focused on HIV-related cardiovascular disease Medicare Card, NIH launches largest clinical trial focused on HIV-related cardiovascular disease...
  4. Medicare Card, NIH launches trial of investigational genital herpes vaccine Medicare Card, NIH launches trial of investigational genital herpes vaccine...
  5. Chikungunya vaccine trial begins to enroll participants An experimental vaccine to prevent chikungunya fever, a viral disease spread by certain species of mosquitoes, is being tested in a clinical trial conducted by National Institute of Allergy and Infectious Diseases (NIAID) scientists at the National Institutes of Health....
  6. Medicare Card, Testing of investigational inactivated Zika vaccine in humans begins Medicare Card, Testing of investigational inactivated Zika vaccine in humans begins...
  7. Medicare Card, NIH begins testing investigational Zika vaccine in humans Medicare Card, NIH begins testing investigational Zika vaccine in humans...
  8. Medicare Card, NIH-funded trial launched to assess experimental TB drug Medicare Card, NIH-funded trial launched to assess experimental TB drug...
  9. Medicare Card, NIH researchers use brain imaging to understand genetic link between Parkinson’s and a rare disease Medicare Card, NIH researchers use brain imaging to understand genetic link between Parkinson’s and a rare disease...
  10. Medicare Card, Large-scale HIV vaccine trial to launch in South Africa Medicare Card, Large-scale HIV vaccine trial to launch in South Africa...
  11. Medicare Card, New NIH-funded memory drug moves into Phase 1 clinical study Medicare Card, New NIH-funded memory drug moves into Phase 1 clinical study...
  12. Medicare Card, NIH-developed candidate dengue vaccine shows promise in early-stage trial Medicare Card, NIH-developed candidate dengue vaccine shows promise in early-stage trial...
  13. Medicare Card, Adults stop anti-rejection drugs after partial stem-cell transplant reverses sickle cell disease NIH trial success suggests a new treatment option for older, sicker patients.   Half of patients in a trial have safely stopped immunosuppressant medication following a modified blood stem-cell transplant for severe sickle cell disease, according to a study in the July 1 issue of the Journal of the American Medical Association External Web Site Policy. […]...
  14. Medicare Card, Seven genetic risk factors found to be associated with common eye disorder Medicare Card, Seven genetic risk factors found to be associated with common eye disorder...
  15. Adverse Cardiovascular Events Reported in Testosterone Trial in Older Men A clinical trial of testosterone treatment in older men, reported June 30 online in the New England Journal of Medicine, has found a higher rate of adverse cardiovascular events, such as heart attacks and elevated blood pressure, in a group of older men receiving testosterone gel compared to those receiving placebo. Due to these events, […]...